Clinical Trial Update: CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial investigating CPI-613 (devimistat) in patients with previously treated myelodysplastic syndromes. The study was terminated and results were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• CPI-613 (devimistat)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Previously Treated Myelodysplastic Syndromes | Phase 2 | Status: TERMINATED | Results posted: 2024-10-17